The relationship between the acquired form of aplastic anaemia (AA) and paroxysmal nocturnal haemoglobinuria (PNH) has been well described (Lewis & Dacie, 1967) . PNH is an acquired stem cell disorder due to the expansion of a haematopoietic progenitor cell that has acquired a mutation in the X-linked PIGA gene. The PIGA gene encodes an enzyme subunit that is essential in the biosynthesis of glycosyl phosphatidylinositol (GPI)-anchor molecules. Thus, patients with PNH have a proportion of blood cells deficient in all GPI-anchored proteins (Rosse & Ware, 1995) . The acquired form of AA is thought to be mainly immunemediated (Young & Maciejewski, 1997) . PNH is often diagnosed in AA patients and up to 50% of patients with AA may have a detectable PNH clone at the time of diagnosis (Schrezenmeier et al, 1995) .
Recently, high-dose cyclophosphamide (HD CY) has been shown to be effective in the treatment of aplastic anaemia (AA) (Brodsky et al, 1996; Tisdale et al, 2000; Brodsky, 2002) . In a pilot study, no evidence of evolution to a clonal disorder, including PNH, was found among surviving patients that had been treated with HD CY, suggesting that this drug might eradicate mutant clones by its direct cytotoxic effects (Brodsky et al, 1996) . A subsequent prospective randomized trial comparing HD CY + cyclosporine (CSA) with the standard regimen of antithymocyte globulin + CSA in newly diagnosed AA patients was initiated (Tisdale et al, 2000) . However, this study was prematurely terminated as a result of high morbidity and mortality among patents in the HD CY group. The reason for the early termination was the drug's toxicity, causing prolonged neutropenia and severe infection. None of the patients developed PNH over the course of the study and the size of the PNH clone was unchanged in the three patients with pre-existing PNH. However, long-term follow-up of these patients is still pending.
The issue of whether or not patients treated with HD CY have a less frequent incidence of clonal blood disorders remains controversial. To determine whether treatment with HD CY is effective in either eliminating or suppressing the PNH stem cells, we decided to treat mice that have a proportion of blood cells deficient in GPI-anchor proteins (Tremml et al, 1999) with HD CY.
MATERIALS AND METHODS
Mice mosaic for PIGA -cells (Tremml et al, 1999) received intraperitoneal injections of high-dose cyclophosphamide, 200 mg/kg (n ¼ 13) or 400 mg/kg (n ¼ 4) over 4 d consecutively. Syngeneic control mice (n ¼ 6) injected with equal doses of HD CY and untreated mosaic mice (n ¼ 13) were used as controls. Peripheral blood was analysed for complete blood counts, reticulocyte count, and for the proportion of PIGA -blood cells in the red cell, B-cell, T-cell and granulocyte compartments. GPI-anchor molecules and lineage-specific antigens were measured by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA) using fluorescein isothiocyanate (FITC)-conjugated monoclonal antibodies against the proteins as described previously (Rosti et al, 1997 ). The mice were followed for 4 months.
RESULTS
The mice tolerated the daily intraperitoneal injections of HD CY well and showed no signs of distress throughout the 4-month period of follow-up. Intraperitoneally applied CY has previously been shown to be myelosuppressive in mice at a single dose of 50 mg/kg and is usually lethal at 400 mg/kg when given in one dose (Rosenoff et al, 1975) . Reticulocyte counts were obtained in order to assess the degree of bone marrow suppression. Reticulocytopenia was most pronounced between d 2 and 7, followed by reticulocytosis, indicating bone marrow recovery. Haemoglobin values and platelet and peripheral neutrophil counts were lowest on d 8 and peaked around d 14 before returning to near baseline values by d 28 (Fig 1) . Myelosuppression was more pronounced in mice treated with 400 mg/kg than in animals treated with 200 mg/kg (Fig 1) but was not significantly different between the groups of mice with and without PIGA -blood cells (data not shown). Under laboratory conditions, the proportion of PIGA -blood cells in our mice was very stable throughout life (Tremml et al, 1999) . The proportion of PIGA -cells within the peripheral red blood cell compartment showed some variation during the treatment and follow-up period, but no consistent increase or decrease was observed (Fig 2) . Likewise, the changes in the percentages of PIGA -neutrophils and lymphocytes were not significantly different before and after HD CY treatment or for mice that did not receive HD CY (P > 0AE05). The reason for the increase in PIGA -cells observed in one animal is unclear and was not reproduced in subsequent experiments. 
DISCUSSION
The actual pathogenesis of PNH is unknown. In the setting of bone marrow failure, it is believed that the absence of GPI-anchored molecules on the surface of blood cells provides a survival advantage, enabling expansion of the PNH clone (reviewed in Bessler et al, 2001) . PNH, although not a malignant disease as such, is often associated with considerable morbidity and mortality, thus, preliminary data regarding HD CY were promising. Possible mechanisms that might influence clonal evolution include that immune suppression with HD CY may modify the discussed autoimmune destruction of haematopoietic cells in AA patients so that PNH cells no longer have a survival advantage. Alternatively, the cytotoxic effect of the drug may directly damage or suppress PNH stem cells.
In our experiments, HD CY treatment of mice resulted in a transient myelosuppression, causing a transient cytopenia in all blood lineages. However, no consistent effect on the proportion of PIGA -cells in peripheral blood of these animals was documented. These results suggest that PIGA -cells do not have an increased sensitivity to HD CY. Our results are consistent with the observation in three PNH patients included in an early terminated study (Tisdale et al, 2000) in whom the proportion of PIG-cells remained unchanged after HD CY treatment.
In summary, HD CY treatment in mice carrying preexisting PIGA -cells was not efficacious in either suppressing or eradicating PIGA -haematopoietic stem cells. In patients, PIGA -cells are often detectable in the early stages of AA (Dunn et al, 1999) and our findings indicate that HD CY treatment had no effect on the proportion of PIGA -cells. Thus, in combination with the prolonged myelotoxicity seen following treatment (Tisdale et al, 2000) , HD CY may not be an appropriate option for the treatment of patients with established PNH. 
